Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Regeneron Pharmaceuticals

Both of these companies have potential catalysts on the way.

2 Top Biotech Stocks to Buy in November

Shares of Gilead Sciences have been have been on a tear recently.

Has This Hot Stock Run Out of Steam?

The company's growing oncology portfolio is driving increased revenues.

Why Shares of Gilead Sciences Rose 27.20% in October

Twitter

Gilead Sciences Inc said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company.

Gilead, Kite in process of pausing Twitter advertising

AbbVie

Johnson & Johnson

There's no need for agonizing decision-making with these great dividend stocks.

3 No-Brainer Dividend Stocks to Buy in November

Gilead Sciences, Inc. (NASDAQ: GILD) shares have advanced from $61.45 to $80 since the beginning of October 2022, and the current price stands at $79.46. Gilead Sciences reported better-than-expected third-quarter results last week, and the company's management updated financial guidance for the 2022 fiscal year.

Should I buy Gilead Sciences shares in November 2022?

Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022

U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease

Thursday 10/28/2022's Gilead earnings surprise to the upside was terribly sweet, after years of bitterness. Major revenue drivers were firing on all cylinders.

Peak Gilead

Gilead Sciences Inc (NASDAQ: GILD) ended this week up nearly 20% after reporting its quarterly results that handily topped Street estimates and subsequently winning an upgrade from a Truist analyst. Gilead stock could climb another 15% Robyn Karnauskas now sees upside in the biotech firm to $91 – up another 15% from here.

Gilead stock is not out of room to run just yet: Truist

Kinsale Capital Group

These 2 Stock Winners Topped Apple's Big Gains Friday

Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised

Gilead Sciences, Inc. (NASDAQ:GILD ) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O'Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - CFO Christi Shaw - CEO, Kite Conference Call Participants Chris Schott - JPM Salveen Richter - Goldman Sachs Brian Abrahams - RBC Michael Yee - Jefferies Brian Skorney - Baird Matthew Harrison - Morgan Stanley Tyler Van Buren - Cowen Umer Raffat - Evercore Geoff Meacham - Bank of America Operator Ladies and gentlemen, thank you for your patience, and thank you for attending today's Third Quarter 2022 Gilead Sciences Earnings Conference Call. My name is Amber, and I will be your operator for today's call.

Gilead Sciences, Inc. (GILD) Q3 2022 Earnings Call Transcript

Gilead (GILD) delivered earnings and revenue surprises of 31.94% and 15.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Shares of Gilead Sciences Inc. rose after hours on Thursday after the drug maker reported third-quarter results that topped expectations and boosted its full-year profit and sales outlook.

Gilead stock rises on more upbeat forecasts, while COVID drug sales slide

Gilead reported 79% growth for its cancer drugs late Thursday, helping beat expectations. In response, GILD stock could soar.

With A Breakout On The Line, Gilead Sciences Reports Massive Cancer Drug Sales

Gilead Sciences Announces Third Quarter 2022 Financial Results

Big Pharma will close out this week's earnings reports, with Gilead Sciences (GILD) set to give its Q3 results on October 27. With GILD edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.

Will Gilead Sciences Stock Climb After Q3 Earnings?

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Gilead (GILD) Could Beat Earnings Estimates Again

Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.

What's in Store for Gilead (GILD) This Earnings Season?

Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities

Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.

News for Gilead Sciences Stock (GILD)